^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tyvyt (sintilimab)

    i
    Other names: IBI308, IBI 308, IBI-308, LY-3342901
    Company:
    Eli Lilly, Innovent Biologics, Mankind Pharma
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    Overcoming diagnostic pitfalls in primary gastric squamous cell carcinoma: the imperative of adequate sampling in an elderly female patient, case report. (PubMed, Front Oncol)
    Given the patient's advanced age, poor physical condition, and refusal of surgery, a palliative treatment plan of "Raltitrexed + Sintilimab" was finally decided upon after a multidisciplinary consultation. This case highlights the importance of adequate sampling in the diagnosis of gastric squamous cell carcinoma to avoid misdiagnosis due to limited specimens. It also provides a potential treatment option of immune therapy combined with low-dose chemotherapy for elderly patients with gastric squamous cell carcinoma who are not suitable for surgery.
    Journal
    |
    TP63 (Tumor protein 63) • MUC5AC (Mucin 5AC)
    |
    Tyvyt (sintilimab) • Tomudex (raltitrexed)
    2d
    concept: The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Zhejiang University
    New P2 trial • Checkpoint inhibition • IO biomarker
    |
    BRAF (B-raf proto-oncogene)
    |
    Erbitux (cetuximab) • Vectibix (panitumumab) • Tyvyt (sintilimab) • Fruzaqla (fruquintinib)
    2d
    HASCHANGE02: Perioperative Therapy for HER2-negative Hepatoid Adenocarcinoma of Stomach (clinicaltrials.gov)
    P2, N=30, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    6d
    Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=88, Recruiting, West China Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tyvyt (sintilimab) • oxaliplatin
    7d
    Assessment of the Safety and Efficacy of C019199 Plus Sintilimab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=155, Active, not recruiting, Fujian Haixi Pharmaceuticals Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tyvyt (sintilimab) • C019199
    7d
    CISN-L: Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer (clinicaltrials.gov)
    P2, N=302, Not yet recruiting, First Affiliated Hospital of Wenzhou Medical University
    New P2 trial
    |
    Tyvyt (sintilimab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin
    9d
    NLCCRIT-LARC: Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer (clinicaltrials.gov)
    P2, N=30, Completed, Peking University People's Hospital | Recruiting --> Completed | Trial primary completion date: Jan 2025 --> Apr 2025
    Trial completion • Trial primary completion date
    |
    Tyvyt (sintilimab)
    10d
    Vessels encapsulating tumor clusters is associated with impaired efficacy of adjuvant immunotherapy in resected hepatocellular carcinoma. (PubMed, J Adv Res)
    This study validates VETC-positive HCC as a distinct entity with a high risk of postoperative recurrence and validates the combination of PD-1 inhibitors with Lenvatinib as its preferred therapeutic strategy.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Tyvyt (sintilimab) • Lenvima (lenvatinib)
    11d
    Kirsten rat sarcoma G12C inhibitor treatment for a patient with relapsed metastatic lung adenocarcinoma: A case report. (PubMed, World J Clin Cases)
    After multiple-line treatment including chemotherapy, targeted therapy, and immunotherapy, disease control was achieved in a case of advanced pulmonary adenocarcinoma carrying the KRAS G12C mutation by mutation-specific inhibitor therapy, and the adverse reactions to the therapy were tolerable.
    Preclinical • Journal • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    KRAS mutation
    |
    Avastin (bevacizumab) • cisplatin • docetaxel • Focus V (anlotinib) • Tyvyt (sintilimab) • albumin-bound paclitaxel • pemetrexed • Kaitanni (cadonilimab) • Aqupla (nedaplatin) • ondansetron
    14d
    Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma (clinicaltrials.gov)
    P2, N=50, Active, not recruiting, The First Affiliated Hospital of Anhui Medical University
    New P2 trial
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    15d
    Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma (clinicaltrials.gov)
    P2, N=36, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P2 trial
    |
    Focus V (anlotinib) • Tyvyt (sintilimab)
    15d
    IPIZA: Intraperitoneal Immune Checkpoint Inhibitors and Zoledronic Acids for Gastric Cancer Malignant Ascites (clinicaltrials.gov)
    P1/2, N=24, Recruiting, Qilu Hospital of Shandong University | Trial completion date: Feb 2025 --> Sep 2026 | Trial primary completion date: Feb 2025 --> Sep 2026
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    |
    Tyvyt (sintilimab) • zoledronic acid